Most people with sickle cell disease (SCD) who received a new type of stem cell transplant in a clinical trial were free of disease-related clinical events after two years, according to a study. The scientists said the findings demonstrate that the approach, which uses a lower-intensity conditioning regimen…
News
The incidence of vaso-occlusive episodes and acute chest syndrome in children with sickle cell disease (SCD) is elevated during January to March, a large nationwide, retrospective study in the U.S. suggests. The findings reinforce the need for “recommendations for patients with SCD to take appropriate precautions in cold weather,”…
Sickle cell disease (SCD) is associated with enhanced immune B-cell responses and the production of self-reactive antibodies that target and destroy red blood cells, according to data from a mouse model of the disease and patient samples. These changes in immune responses were regulated by type-1 interferons (IFN-1), an…
A sickle cell disease (SCD) patient in Bahrain received the gene-editing therapy Casgevy (exagamglogene autotemcel), becoming the first patient outside the U.S. to be treated with the drug. Bahrain approved Casgevy in late 2023, becoming the first country in the Middle East to approve the therapy and the…
Some children with sickle cell disease (SCD) may benefit from supplementing with folic acid, according to a clinical trial. Supplementation was found to significantly increase the levels of red blood cell folate, a molecule important for the production of red blood cells, compared with a placebo. However, no differences…
Vertex Pharmaceuticals has entered a reimbursement agreement with the National Health Service in England that will enable eligible sickle cell disease (SCD) patients in that country to get access to treatment with Casgevy (exagamglogene autotemcel) via the public health system. “[This] agreement means eligible sickle cell disease…
Children’s Hospital Los Angeles (CHLA) is now offering Casgevy (exagamglogene autotemcel), an approved gene-editing therapy for sickle cell disease (SCD). “This is a transformative time for Children’s Hospital Los Angeles and the pediatric community we serve,” Alan S. Wayne, MD, pediatrician-in-chief at CHLA, said in a press…
The first patient has been enrolled in a Phase 1 clinical trial evaluating the safety and tolerability of Rigel Pharmaceuticals’ fostamatinib — a medication approved in the U.S. for treating an autoimmune condition — in people with sickle cell disease (SCD). The Phase 1 study (NCT05904093) is…
People with sickle cell disease (SCD) have brains that appear to be more than a decade older than their actual age. That’s according to a recent study that also found that patients with older-looking brains had poorer cognitive function. “Our study explains how a chronic illness … can cause…
Immvention Therapeutix has partnered with Novo Nordisk to develop oral treatments for people with sickle cell disease (SCD) and other chronic conditions. The U.S.-based Immvention called the deal “a strategic collaboration and license agreement” in a company press release. “We are excited to partner with Novo…
Recent Posts
- Tips for enjoying the most wonderful time of the year with sickle cell
- Big Nova donates $3M to expand access to stem cell transplants
- Investigational SCD therapy shows stronger results at higher dose
- Risto-cel showing lasting benefits for people with severe SCD in trial
- The price of living with a physical disability in a non-inclusive society
- Casgevy safely prevents sickle cell crises in children: Trial data
- Curcumin skin gel shown to improve heart health in SCD mice
- Socioeconomic status not linked to stroke risk in children with SCD
- Weathering the stages of denial before reaching acceptance
- New Aflac children’s book supports youngsters with SCD, cancer